Key result
This review describes the possible pathophysiological links between COVID-19 and atrial fibrillation, highlighting therapeutic considerations for managing AF patients during the pandemic.
Why the study?
The high contagiousness of COVID-19 and premature therapies against the virus make the management of patients with AF during the pandemic particularly challenging.
This review outlines the pathophysiological links between COVID-19 and atrial fibrillation, along with therapeutic considerations for managing AF during the pandemic.
AF management in COVID-19 demands individualized caution; leaves open optimal anticoagulation and rhythm strategies.
The health crisis due to coronavirus disease 2019 (COVID-19) shocks the world with more than million infections and casualties. COVID-19 could present from mild illness to multi-organ involvement, especially acute respiratory distress syndrome. Cardiac injury and arrhythmias including atrial fibrillation (AF) are not uncommon in COVID-19. COVID-19 is highly contagious, and the therapy against the virus remains premature and largely unknown. These make the management of AF patients during pandemic particularly challenging. We here describe possible pathophysiology link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2020) conducted a review in Atrial Fibrillation and COVID-19. This review describes the possible pathophysiological links between COVID-19 and atrial fibrillation, highlighting therapeutic considerations for managing AF patients during the pandemic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: